Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Aquamin F** is a seaweed-derived multi-mineral nutraceutical developed by Marigot for symptomatic knee osteoarthritis. It is produced from calcified red algae and provides calcium, magnesium, and numerous trace minerals; it is not a conventional single-molecule pharmaceutical and has no established discrete molecular target. Its proposed activity is nutritional mineral repletion and support of joint function, with possible indirect effects on inflammatory processes and musculoskeletal health. In randomized placebo-controlled studies in moderate-to-severe knee osteoarthritis, oral Aquamin F at 2,400 mg/day for up to 12 weeks was evaluated for effects on pain, stiffness, mobility, walking distance, range of motion, and NSAID-use reduction. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2642861/))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aquamin F.